Exchange: NASDAQ·Updated 05:44 AM EDT
GOSS logo

GOSS Gossamer Bio Inc

$0.1722
$0.0005
(0.29%)
Pre-Market
Prev Close $0.1727
Reported EarningsAug 13
Mkt Cap$81.83M
Vol51,260.00

About GOSS

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.
48

Neutral Sentiment

How do you feel about GOSS?

Advertisement|Remove ads.